-
1
-
-
84965092294
-
Cancer-a biological approach: I. The processes of control. II. The significance of somatic mutation
-
Burnet FM: Cancer-a biological approach: I. The processes of control. II. The significance of somatic mutation. Brit Med J 1957, 1:779-786.
-
(1957)
Brit Med J
, vol.1
, pp. 779-786
-
-
Burnet, F.M.1
-
2
-
-
0036852241
-
Cancer immunoediting: from immunosurveillance to tumor escape
-
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
-
(2002)
Nat Immunol
, vol.3
, pp. 991-998
-
-
Dunn, G.P.1
Bruce, A.T.2
Ikeda, H.3
Old, L.J.4
Schreiber, R.D.5
-
3
-
-
0028500836
-
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors
-
Dighe AS, Richards E, Old LJ, Schreiber RD: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994, 1:447-456.
-
(1994)
Immunity
, vol.1
, pp. 447-456
-
-
Dighe, A.S.1
Richards, E.2
Old, L.J.3
Schreiber, R.D.4
-
4
-
-
0036005884
-
The roles of IFN gamma in protection against tumor development and cancer immunoediting
-
Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002, 13:95-109.
-
(2002)
Cytokine Growth Factor Rev
, vol.13
, pp. 95-109
-
-
Ikeda, H.1
Old, L.J.2
Schreiber, R.D.3
-
5
-
-
0004068373
-
Malignant Tumors in Organ Transplant Recipients
-
Heidelberg: Springer-Verlag
-
Penn I: Malignant Tumors in Organ Transplant Recipients. In Recent Results in Cancer, Volume 35. Heidelberg: Springer-Verlag; 1970:1-55.
-
(1970)
Recent Results in Cancer
, vol.35
, pp. 1-55
-
-
Penn, I.1
-
6
-
-
0033056609
-
Posttransplant malignancies
-
Penn I: Posttransplant malignancies. Transplant Proc 1999, 31:1260-1262.
-
(1999)
Transplant Proc
, vol.31
, pp. 1260-1262
-
-
Penn, I.1
-
7
-
-
0015098830
-
Occurrence of malignancy in immunodeficiency diseases. A literature review
-
Gatti RA, Good RA: Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971, 28:89-98.
-
(1971)
Cancer
, vol.28
, pp. 89-98
-
-
Gatti, R.A.1
Good, R.A.2
-
8
-
-
0030040747
-
Malignant melanoma in organ allograft recipients
-
Penn I: Malignant melanoma in organ allograft recipients. Transplantation 1996, 61:274-278.
-
(1996)
Transplantation
, vol.61
, pp. 274-278
-
-
Penn, I.1
-
9
-
-
33846636409
-
Differential antigen processing by dendritic cell subsets in vivo
-
Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC: Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
-
(2007)
Science
, vol.315
, pp. 107-111
-
-
Dudziak, D.1
Kamphorst, A.O.2
Heidkamp, G.F.3
Buchholz, V.R.4
Trumpfheller, C.5
Yamazaki, S.6
Cheong, C.7
Liu, K.8
Lee, H.W.9
Park, C.G.10
Steinman, R.M.11
Nussenzweig, M.C.12
-
10
-
-
56449097442
-
Batf3 deficiency reveals a critical role for CD8alpha + dendritic cells in cytotoxic T cell immunity
-
Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM: Batf3 deficiency reveals a critical role for CD8alpha + dendritic cells in cytotoxic T cell immunity. Science 2008, 322:1097-1100.
-
(2008)
Science
, vol.322
, pp. 1097-1100
-
-
Hildner, K.1
Edelson, B.T.2
Purtha, W.E.3
Diamond, M.4
Matsushita, H.5
Kohyama, M.6
Calderon, B.7
Schraml, B.U.8
Unanue, E.R.9
Diamond, M.S.10
Schreiber, R.D.11
Murphy, T.L.12
Murphy, K.M.13
-
11
-
-
80355136945
-
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha} + dendritic cells
-
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF: Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha} + dendritic cells. J Exp Med 2011, 208:2005-2016.
-
(2011)
J Exp Med
, vol.208
, pp. 2005-2016
-
-
Fuertes, M.B.1
Kacha, A.K.2
Kline, J.3
Woo, S.R.4
Kranz, D.M.5
Murphy, K.M.6
Gajewski, T.F.7
-
12
-
-
77953484184
-
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha + dendritic cells
-
Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reise Sousa C: Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha + dendritic cells. J Exp Med 2010, 207:1261-1271.
-
(2010)
J Exp Med
, vol.207
, pp. 1261-1271
-
-
Poulin, L.F.1
Salio, M.2
Griessinger, E.3
Anjos-Afonso, F.4
Craciun, L.5
Chen, J.L.6
Keller, A.M.7
Joffre, O.8
Zelenay, S.9
Nye, E.10
Le Moine, A.11
Faure, F.12
Donckier, V.13
Sancho, D.14
Cerundolo, V.15
Bonnet, D.16
Reise Sousa, C.17
-
13
-
-
80355147292
-
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
-
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD: Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208:1989-2003.
-
(2011)
J Exp Med
, vol.208
, pp. 1989-2003
-
-
Diamond, M.S.1
Kinder, M.2
Matsushita, H.3
Mashayekhi, M.4
Dunn, G.P.5
Archambault, J.M.6
Lee, H.7
Arthur, C.D.8
White, J.M.9
Kalinke, U.10
Murphy, K.M.11
Schreiber, R.D.12
-
14
-
-
84863275160
-
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation
-
Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF: Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 2012, 188:2630-2642.
-
(2012)
J Immunol
, vol.188
, pp. 2630-2642
-
-
Kline, J.1
Zhang, L.2
Battaglia, L.3
Cohen, K.S.4
Gajewski, T.F.5
-
15
-
-
84860240081
-
DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues
-
Poulin LF, Reyal Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, Håkansson UK, Moita LF, Agace WW, Bonnet D, Reise Sousa C: DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 2012, 119:6052-6062.
-
(2012)
Blood
, vol.119
, pp. 6052-6062
-
-
Poulin, L.F.1
Reyal, Y.2
Uronen-Hansson, H.3
Schraml, B.U.4
Sancho, D.5
Murphy, K.M.6
Håkansson, U.K.7
Moita, L.F.8
Agace, W.W.9
Bonnet, D.10
Reise Sousa, C.11
-
16
-
-
84860007667
-
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor crosspriming of CTLs in virus-infected mice
-
Zelenay S, Keller AM, Whitney PG, Schraml BU, Deddouche S, Rogers NC, Schulz O, Sancho D, Reise Sousa C: The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor crosspriming of CTLs in virus-infected mice. J Clin Invest 2012, 122:1615-1627.
-
(2012)
J Clin Invest
, vol.122
, pp. 1615-1627
-
-
Zelenay, S.1
Keller, A.M.2
Whitney, P.G.3
Schraml, B.U.4
Deddouche, S.5
Rogers, N.C.6
Schulz, O.7
Sancho, D.8
Reise Sousa, C.9
-
17
-
-
0030051657
-
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo
-
Fallarino F, Uyttenhove C, Boon T, Gajewski TF: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 1996, 156:1095-1100.
-
(1996)
J Immunol
, vol.156
, pp. 1095-1100
-
-
Fallarino, F.1
Uyttenhove, C.2
Boon, T.3
Gajewski, T.F.4
-
18
-
-
66149156276
-
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
-
Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski T: Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69:3077-3085.
-
(2009)
Cancer Res
, vol.69
, pp. 3077-3085
-
-
Harlin, H.1
Meng, Y.2
Peterson, A.C.3
Zha, Y.4
Tretiakova, M.5
Slingluff, C.6
McKee, M.7
Gajewski, T.8
-
19
-
-
38049000452
-
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
-
Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G: Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36.
-
(2008)
Nat Med
, vol.14
, pp. 28-36
-
-
Buckanovich, R.J.1
Facciabene, A.2
Kim, S.3
Benencia, F.4
Sasaroli, D.5
Balint, K.6
Katsaros, D.7
O'Brien-Jenkins, A.8
Gimotty, P.A.9
Coukos, G.10
-
20
-
-
78149309084
-
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase
-
Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H: Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010, 207:2469-2477.
-
(2010)
J Exp Med
, vol.207
, pp. 2469-2477
-
-
Schietinger, A.1
Philip, M.2
Liu, R.B.3
Schreiber, K.4
Schreiber, H.5
-
21
-
-
78650919399
-
Translating tumor antigens into cancer vaccines
-
Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM: Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011, 18:23-34.
-
(2011)
Clin Vaccine Immunol
, vol.18
, pp. 23-34
-
-
Buonaguro, L.1
Petrizzo, A.2
Tornesello, M.L.3
Buonaguro, F.M.4
-
22
-
-
69049089548
-
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
-
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5323-5337
-
-
Cheever, M.A.1
Allison, J.P.2
Ferris, A.S.3
Finn, O.J.4
Hastings, B.M.5
Hecht, T.T.6
Mellman, I.7
Prindiville, S.A.8
Viner, J.L.9
Weiner, L.M.10
Matrisian, L.M.11
-
23
-
-
84864380076
-
MAGE-A antigens as targets in tumour therapy
-
Meek DW, Marcar L: MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012, 324:126-132.
-
(2012)
Cancer Lett
, vol.324
, pp. 126-132
-
-
Meek, D.W.1
Marcar, L.2
-
24
-
-
78349289653
-
The SSX family of cancer-testis antigens as target proteins for tumor therapy
-
Smith HA, McNeel DG: The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010, 2010:150591.
-
(2010)
Clin Dev Immunol
, vol.2010
-
-
Smith, H.A.1
McNeel, D.G.2
-
25
-
-
80052065824
-
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
-
Straten PT, Andersen MH: The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget 2010, 1:239-245.
-
(2010)
Oncotarget
, vol.1
, pp. 239-245
-
-
Straten, P.T.1
Andersen, M.H.2
-
26
-
-
77955066199
-
Sipuleucel-T immunotherapy for castrationresistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators: Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010, 363:411-422.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
Redfern, C.H.7
Ferrari, A.C.8
Dreicer, R.9
Sims, R.B.10
Xu, Y.11
Frohlich, M.W.12
Schellhammer, P.F.13
-
27
-
-
77953473376
-
MAGE A3 antigen-specific cancer immunotherapeutic
-
Peled N, Oton AB, Hirsch FR, Bunn P: MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy 2009, 1:19-25.
-
(2009)
Immunotherapy
, vol.1
, pp. 19-25
-
-
Peled, N.1
Oton, A.B.2
Hirsch, F.R.3
Bunn, P.4
-
28
-
-
77249089345
-
MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy
-
Tyagi P, Mirakhur B: MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009, 10:371-374.
-
(2009)
Clin Lung Cancer
, vol.10
, pp. 371-374
-
-
Tyagi, P.1
Mirakhur, B.2
-
29
-
-
77949895922
-
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
-
Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1099-1105
-
-
Kantoff, P.W.1
Schuetz, T.J.2
Blumenstein, B.A.3
Glode, L.M.4
Bilhartz, D.L.5
Wyand, M.6
Manson, K.7
Panicali, D.L.8
Laus, R.9
Schlom, J.10
Dahut, W.L.11
Arlen, P.M.12
Gulley, J.L.13
Godfrey, W.R.14
-
30
-
-
55949125601
-
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
-
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5233-5239
-
-
Dudley, M.E.1
Yang, J.C.2
Sherry, R.3
Hughes, M.S.4
Royal, R.5
Kammula, U.6
Robbins, P.F.7
Huang, J.8
Citrin, D.E.9
Leitman, S.F.10
Wunderlich, J.11
Restifo, N.P.12
Thomasian, A.13
Downey, S.G.14
Smith, F.O.15
Klapper, J.16
Morton, K.17
Laurencot, C.18
White, D.E.19
Rosenberg, S.A.20
more..
-
31
-
-
5144226237
-
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes
-
Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14639-14645.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 14639-14645
-
-
Rosenberg, S.A.1
Dudley, M.E.2
-
32
-
-
0037058993
-
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells
-
Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002, 99:16168-16173.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 16168-16173
-
-
Yee, C.1
Thompson, J.A.2
Byrd, D.3
Riddell, S.R.4
Roche, P.5
Celis, E.6
Greenberg, P.D.7
-
33
-
-
84863337726
-
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype
-
Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C: Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012, 109:4592-4597.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 4592-4597
-
-
Chapuis, A.G.1
Thompson, J.A.2
Margolin, K.A.3
Rodmyre, R.4
Lai, I.P.5
Dowdy, K.6
Farrar, E.A.7
Bhatia, S.8
Sabath, D.E.9
Cao, J.10
Li, Y.11
Yee, C.12
-
34
-
-
45549099784
-
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
-
Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl JMed 2008, 358:2698-2703.
-
(2008)
N Engl JMed
, vol.358
, pp. 2698-2703
-
-
Hunder, N.N.1
Wallen, H.2
Cao, J.3
Hendricks, D.W.4
Reilly, J.Z.5
Rodmyre, R.6
Jungbluth, A.7
Gnjatic, S.8
Thompson, J.A.9
Yee, C.10
-
35
-
-
33749624177
-
Cancer regression in patients after transfer of genetically engineered lymphocytes
-
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
-
(2006)
Science
, vol.314
, pp. 126-129
-
-
Morgan, R.A.1
Dudley, M.E.2
Wunderlich, J.R.3
Hughes, M.S.4
Yang, J.C.5
Sherry, R.M.6
Royal, R.E.7
Topalian, S.L.8
Kammula, U.S.9
Restifo, N.P.10
Zheng, Z.11
Nahvi, A.12
de Vries, C.R.13
Rogers-Freezer, L.J.14
Mavroukakis, S.A.15
Rosenberg, S.A.16
-
36
-
-
78549253550
-
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor
-
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH: Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010, 70:9053-9061.
-
(2010)
Cancer Res
, vol.70
, pp. 9053-9061
-
-
Zhao, Y.1
Moon, E.2
Carpenito, C.3
Paulos, C.M.4
Liu, X.5
Brennan, A.L.6
Chew, A.7
Carroll, R.G.8
Scholler, J.9
Levine, B.L.10
Albelda, S.M.11
June, C.H.12
-
37
-
-
0036276002
-
Interleukin-2: clinical applications
-
Atkins MB: Interleukin-2: clinical applications. Semin Oncol 2002, 29(3 Suppl 7):12-17.
-
(2002)
Semin Oncol
, vol.29
, Issue.3
, pp. 12-17
-
-
Atkins, M.B.1
-
38
-
-
79955418828
-
Harnessing the biology of IL-7 for therapeutic application
-
Mackall CL, Fry TJ, Gress RE: Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
-
(2011)
Nat Rev Immunol
, vol.11
, pp. 330-342
-
-
Mackall, C.L.1
Fry, T.J.2
Gress, R.E.3
-
39
-
-
73849140105
-
Immune modulation with interleukin-21
-
Bhave NS, Carson WE 3rd: Immune modulation with interleukin-21. Ann N Y Acad Sci 2009, 1182:39-46.
-
(2009)
Ann N Y Acad Sci
, vol.1182
, pp. 39-46
-
-
Bhave, N.S.1
Carson, W.E.2
-
40
-
-
84867342693
-
Immunotherapeutic applications of IL-15
-
Croce M, Orengo AM, Azzarone B, Ferrini S: Immunotherapeutic applications of IL-15. Immunotherapy 2012, 4:957-969.
-
(2012)
Immunotherapy
, vol.4
, pp. 957-969
-
-
Croce, M.1
Orengo, A.M.2
Azzarone, B.3
Ferrini, S.4
-
41
-
-
0028114542
-
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor
-
Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D'Andrea AD, Ritz J, Nadler LM: Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994, 266:1039-1042.
-
(1994)
Science
, vol.266
, pp. 1039-1042
-
-
Boussiotis, V.A.1
Barber, D.L.2
Nakarai, T.3
Freeman, G.J.4
Gribben, J.G.5
Bernstein, G.M.6
D'Andrea, A.D.7
Ritz, J.8
Nadler, L.M.9
-
42
-
-
34447302212
-
The role of cytokines which signal through the common gamma chain cytokine receptor in the reversal of HIV specific CD4(+) and CD8(+) T cell anergy
-
Gu XX, Yue FY, Kovacs CM, Ostrowski MA: The role of cytokines which signal through the common gamma chain cytokine receptor in the reversal of HIV specific CD4(+) and CD8(+) T cell anergy. PLoS One 2007, 2:e300.
-
(2007)
PLoS One
, vol.2
-
-
Gu, X.X.1
Yue, F.Y.2
Kovacs, C.M.3
Ostrowski, M.A.4
-
43
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
Akerley, W.11
van den Eertwegh, A.J.12
Lutzky, J.13
Lorigan, P.14
Vaubel, J.M.15
Linette, G.P.16
Hogg, D.17
Ottensmeier, C.H.18
Lebbé, C.19
Peschel, C.20
Quirt, I.21
Clark, J.I.22
Wolchok, J.D.23
Weber, J.S.24
Tian, J.25
Yellin, M.J.26
Nichol, G.M.27
Hoos, A.28
Urba, W.J.29
more..
-
44
-
-
84862739640
-
Immunotherapy of cancer with 4-1BB
-
Vinay DS, Kwon BS: Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11:1062-1070.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 1062-1070
-
-
Vinay, D.S.1
Kwon, B.S.2
-
45
-
-
78449237498
-
Signaling through OX40 enhances antitumor immunity
-
Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti BD, Fox BA: Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010, 37:524-532.
-
(2010)
Semin Oncol
, vol.37
, pp. 524-532
-
-
Jensen, S.M.1
Maston, L.D.2
Gough, M.J.3
Ruby, C.E.4
Redmond, W.L.5
Crittenden, M.6
Li, Y.7
Puri, S.8
Poehlein, C.H.9
Morris, N.10
Kovacsovics-Bankowski, M.11
Moudgil, T.12
Twitty, C.13
Walker, E.B.14
Hu, H.M.15
Urba, W.J.16
Weinberg, A.D.17
Curti, B.D.18
Fox, B.A.19
-
46
-
-
33748416499
-
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
-
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355:1018-1028.
-
(2006)
N Engl J Med
, vol.355
, pp. 1018-1028
-
-
Suntharalingam, G.1
Perry, M.R.2
Ward, S.3
Brett, S.J.4
Castello-Cortes, A.5
Brunner, M.D.6
Panoskaltsis, N.7
-
47
-
-
84884271914
-
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
-
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
-
(2013)
J Exp Med
, vol.210
, pp. 1695-1710
-
-
Simpson, T.R.1
Li, F.2
Montalvo-Ortiz, W.3
Sepulveda, M.A.4
Bergerhoff, K.5
Arce, F.6
Roddie, C.7
Henry, J.Y.8
Yagita, H.9
Wolchok, J.D.10
Peggs, K.S.11
Ravetch, J.V.12
Allison, J.P.13
Quezada, S.A.14
-
48
-
-
33745632047
-
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites
-
Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF: Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006, 55:1185-1197.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 1185-1197
-
-
Harlin, H.1
Kuna, T.V.2
Peterson, A.C.3
Meng, Y.4
Gajewski, T.F.5
-
49
-
-
0038181111
-
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma
-
Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A: Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003, 63:2535-2545.
-
(2003)
Cancer Res
, vol.63
, pp. 2535-2545
-
-
Mortarini, R.1
Piris, A.2
Maurichi, A.3
Molla, A.4
Bersani, I.5
Bono, A.6
Bartoli, C.7
Santinami, M.8
Lombardo, C.9
Ravagnani, F.10
Cascinelli, N.11
Parmiani, G.12
Anichini, A.13
-
50
-
-
33746214819
-
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
-
Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE: New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006, 177:1670-1678.
-
(2006)
J Immunol
, vol.177
, pp. 1670-1678
-
-
Appay, V.1
Jandus, C.2
Voelter, V.3
Reynard, S.4
Coupland, S.E.5
Rimoldi, D.6
Lienard, D.7
Guillaume, P.8
Krieg, A.M.9
Cerottini, J.C.10
Romero, P.11
Leyvraz, S.12
Rufer, N.13
Speiser, D.E.14
-
51
-
-
65349156913
-
Costimulatory and coinhibitory receptors in anti-tumor immunity
-
Driessens G, Kline J, Gajewski TF: Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009, 229:126-144.
-
(2009)
Immunol Rev
, vol.229
, pp. 126-144
-
-
Driessens, G.1
Kline, J.2
Gajewski, T.F.3
-
52
-
-
84860427686
-
Cancer immunotherapy
-
Gajewski TF: Cancer immunotherapy. Mol Oncol 2012, 6:242-250.
-
(2012)
Mol Oncol
, vol.6
, pp. 242-250
-
-
Gajewski, T.F.1
-
53
-
-
84883863501
-
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
-
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 2013, 5:200ra116.
-
(2013)
Sci Transl Med
, vol.5
-
-
Spranger, S.1
Spaapen, R.M.2
Zha, Y.3
Williams, J.4
Meng, Y.5
Ha, T.T.6
Gajewski, T.F.7
-
54
-
-
84877132569
-
Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer
-
Chen LJ, Zheng X, Shen YP, Zhu YB, Li Q, Chen J, Xia R, Zhou SM, Wu CP, Zhang XG, Lu BF, Jiang JT: Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother 2013, 62:553-561.
-
(2013)
Cancer Immunol Immunother
, vol.62
, pp. 553-561
-
-
Chen, L.J.1
Zheng, X.2
Shen, Y.P.3
Zhu, Y.B.4
Li, Q.5
Chen, J.6
Xia, R.7
Zhou, S.M.8
Wu, C.P.9
Zhang, X.G.10
Lu, B.F.11
Jiang, J.T.12
-
55
-
-
0026700235
-
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
-
Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895.
-
(1992)
EMBO J
, vol.11
, pp. 3887-3895
-
-
Ishida, Y.1
Agata, Y.2
Shibahara, K.3
Honjo, T.4
-
56
-
-
33745197352
-
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
-
Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006, 119:317-327.
-
(2006)
Int J Cancer
, vol.119
, pp. 317-327
-
-
Blank, C.1
Kuball, J.2
Voelkl, S.3
Wiendl, H.4
Becker, B.5
Walter, B.6
Majdic, O.7
Gajewski, T.F.8
Theobald, M.9
Andreesen, R.10
Mackensen, A.11
-
57
-
-
0037126021
-
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
-
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 12293-12297
-
-
Iwai, Y.1
Ishida, M.2
Tanaka, Y.3
Okazaki, T.4
Honjo, T.5
Minato, N.6
-
58
-
-
13844294372
-
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
-
Iwai Y, Terawaki S, Honjo T: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005, 17:133-144.
-
(2005)
Int Immunol
, vol.17
, pp. 133-144
-
-
Iwai, Y.1
Terawaki, S.2
Honjo, T.3
-
59
-
-
13444270323
-
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
-
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
-
(2005)
Cancer Res
, vol.65
, pp. 1089-1096
-
-
Hirano, F.1
Kaneko, K.2
Tamura, H.3
Dong, H.4
Wang, S.5
Ichikawa, M.6
Rietz, C.7
Flies, D.B.8
Lau, J.S.9
Zhu, G.10
Tamada, K.11
Chen, L.12
-
60
-
-
44349150012
-
Inhibitory B7-family molecules in the tumour microenvironment
-
Zou W, Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8:467-477.
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 467-477
-
-
Zou, W.1
Chen, L.2
-
61
-
-
49649114804
-
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
-
Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3044-3051
-
-
Berger, R.1
Rotem-Yehudar, R.2
Slama, G.3
Landes, S.4
Kneller, A.5
Leiba, M.6
Koren-Michowitz, M.7
Shimoni, A.8
Nagler, A.9
-
62
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
Drake, C.G.7
Camacho, L.H.8
Kauh, J.9
Odunsi, K.10
Pitot, H.C.11
Hamid, O.12
Bhatia, S.13
Martins, R.14
Eaton, K.15
Chen, S.16
Salay, T.M.17
Alaparthy, S.18
Grosso, J.F.19
Korman, A.J.20
Parker, S.M.21
Agrawal, S.22
Goldberg, S.M.23
Pardoll, D.M.24
Gupta, A.25
Wigginton, J.M.26
more..
-
63
-
-
84862859820
-
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012, 366:2443-2454.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
Powderly, J.D.7
Carvajal, R.D.8
Sosman, J.A.9
Atkins, M.B.10
Leming, P.D.11
Spigel, D.R.12
Antonia, S.J.13
Horn, L.14
Drake, C.G.15
Pardoll, D.M.16
Chen, L.17
Sharfman, W.H.18
Anders, R.A.19
Taube, J.M.20
McMiller, T.L.21
Xu, H.22
Korman, A.J.23
Jure-Kunkel, M.24
Agrawal, S.25
McDonald, D.26
Kollia, G.D.27
Gupta, A.28
Wigginton, J.M.29
Sznol, M.30
more..
-
64
-
-
84871196652
-
Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
-
Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, Drengler R, Chen C, Lon S, Perez C, Gergich K, Lehnert M: Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012, 30 (Suppl; abstr 2512).
-
(2012)
J Clin Oncol
, pp. 30
-
-
Patnaik, A.1
Kang, S.P.2
Tolcher, A.W.3
Rasco, D.W.4
Papadopoulos, K.P.5
Beeram, M.6
Drengler, R.7
Chen, C.8
Lon, S.9
Perez, C.10
Gergich, K.11
Lehnert, M.12
-
65
-
-
51049113616
-
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage
-
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP: Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 2008, 68:6054-6058.
-
(2008)
Cancer Res
, vol.68
, pp. 6054-6058
-
-
Thompson, R.H.1
Zang, X.2
Lohse, C.M.3
Leibovich, B.C.4
Slovin, S.F.5
Reuter, V.E.6
Cheville, J.C.7
Blute, M.L.8
Russo, P.9
Kwon, E.D.10
Allison, J.P.11
-
66
-
-
37649013179
-
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
-
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007, 104:19458-19463.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 19458-19463
-
-
Zang, X.1
Thompson, R.H.2
Al-Ahmadie, H.A.3
Serio, A.M.4
Reuter, V.E.5
Eastham, J.A.6
Scardino, P.T.7
Sharma, P.8
Allison, J.P.9
-
67
-
-
84863928141
-
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity
-
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA: Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 2012, 18:3834-3845.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3834-3845
-
-
Loo, D.1
Alderson, R.F.2
Chen, F.Z.3
Huang, L.4
Zhang, W.5
Gorlatov, S.6
Burke, S.7
Ciccarone, V.8
Li, H.9
Yang, Y.10
Son, T.11
Chen, Y.12
Easton, A.N.13
Li, J.C.14
Rillema, J.R.15
Licea, M.16
Fieger, C.17
Liang, T.W.18
Mather, J.P.19
Koenig, S.20
Stewart, S.J.21
Johnson, S.22
Bonvini, E.23
Moore, P.A.24
more..
-
68
-
-
81255138408
-
Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives
-
Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R: Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011, 17:6985-6991.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6985-6991
-
-
Godin-Ethier, J.1
Hanafi, L.A.2
Piccirillo, C.A.3
Lapointe, R.4
-
69
-
-
0037136328
-
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase
-
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002, 196:459-468.
-
(2002)
J Exp Med
, vol.196
, pp. 459-468
-
-
Frumento, G.1
Rotondo, R.2
Tonetti, M.3
Damonte, G.4
Benatti, U.5
Ferrara, G.B.6
-
70
-
-
18544364477
-
Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase
-
Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL: Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 2002, 297:1867-1870.
-
(2002)
Science
, vol.297
, pp. 1867-1870
-
-
Munn, D.H.1
Sharma, M.D.2
Lee, J.R.3
Jhaver, K.G.4
Johnson, T.S.5
Keskin, D.B.6
Marshall, B.7
Chandler, P.8
Antonia, S.J.9
Burgess, R.10
Slingluff, C.L.11
Mellor, A.L.12
-
71
-
-
0142137237
-
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase
-
Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003, 9:1269-1274.
-
(2003)
Nat Med
, vol.9
, pp. 1269-1274
-
-
Uyttenhove, C.1
Pilotte, L.2
Théate, I.3
Stroobant, V.4
Colau, D.5
Parmentier, N.6
Boon, T.7
Van den Eynde, B.J.8
-
72
-
-
77951718214
-
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
-
Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA: Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115:3520-3530.
-
(2010)
Blood
, vol.115
, pp. 3520-3530
-
-
Liu, X.1
Shin, N.2
Koblish, H.K.3
Yang, G.4
Wang, Q.5
Wang, K.6
Leffet, L.7
Hansbury, M.J.8
Thomas, B.9
Rupar, M.10
Waeltz, P.11
Bowman, K.J.12
Polam, P.13
Sparks, R.B.14
Yue, E.W.15
Li, Y.16
Wynn, R.17
Fridman, J.S.18
Burn, T.C.19
Combs, A.P.20
Newton, R.C.21
Scherle, P.A.22
more..
-
73
-
-
84870426822
-
Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), in advanced cancer patients
-
Newton RC, Scherle PA, Bowman K, Liu X, Beatty GL, O'Dwyer PJ, Gajewski T, Bowman J, Schaub R, Leopold L: Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), in advanced cancer patients. J Clin Oncol 2012, 30:18 (Suppl; abstr 2500^).
-
(2012)
J Clin Oncol
, vol.30
, pp. 18
-
-
Newton, R.C.1
Scherle, P.A.2
Bowman, K.3
Liu, X.4
Beatty, G.L.5
O'Dwyer, P.J.6
Gajewski, T.7
Bowman, J.8
Schaub, R.9
Leopold, L.10
-
76
-
-
84873406980
-
A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies
-
Soliman HH, Neuger A, Noyes D, Vahanian NN, Link CJ, Munn D, Streicher H, Sullivan D, Antonia S: A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies. J Clin Oncol 2012, 30. Suppl; abstr 2501.
-
(2012)
J Clin Oncol
, pp. 30
-
-
Soliman, H.H.1
Neuger, A.2
Noyes, D.3
Vahanian, N.N.4
Link, C.J.5
Munn, D.6
Streicher, H.7
Sullivan, D.8
Antonia, S.9
-
78
-
-
84991036089
-
-
NCT01191216 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
-
NCT01191216 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors. [http://clinicaltrials.gov/ct2/show/NCT01191216?term=1-Methyl-D-Tryptophan&rank=3]
-
-
-
-
79
-
-
84866916560
-
Metabolism of L-arginine by myeloidderived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives
-
Raber P, Ochoa AC, Rodríguez PC: Metabolism of L-arginine by myeloidderived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012, 41:614-634.
-
(2012)
Immunol Invest
, vol.41
, pp. 614-634
-
-
Raber, P.1
Ochoa, A.C.2
Rodríguez, P.C.3
-
80
-
-
0347785480
-
Control of regulatory T cell development by the transcription factor Foxp3
-
Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
-
(2003)
Science
, vol.299
, pp. 1057-1061
-
-
Hori, S.1
Nomura, T.2
Sakaguchi, S.3
-
81
-
-
65949111746
-
FOXP3 defines regulatory T cells in human tumor and autoimmune disease
-
Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W: FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009, 69:3995-4000.
-
(2009)
Cancer Res
, vol.69
, pp. 3995-4000
-
-
Kryczek, I.1
Liu, R.2
Wang, G.3
Wu, K.4
Shu, X.5
Szeliga, W.6
Vatan, L.7
Finlayson, E.8
Huang, E.9
Simeone, D.10
Redman, B.11
Welling, T.H.12
Chang, A.13
Zou, W.14
-
82
-
-
0141891466
-
Increased populations of regulatory T cells in peripheral blood and tumorinfiltrating lymphocytes in patients with gastric and esophageal cancers
-
Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumorinfiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003, 9:4404-4408.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 4404-4408
-
-
Ichihara, F.1
Kono, K.2
Takahashi, A.3
Kawaida, H.4
Sugai, H.5
Fujii, H.6
-
83
-
-
0036721629
-
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
-
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
-
(2002)
J Immunol
, vol.169
, pp. 2756-2761
-
-
Liyanage, U.K.1
Moore, T.T.2
Joo, H.G.3
Tanaka, Y.4
Herrmann, V.5
Doherty, G.6
Drebin, J.A.7
Strasberg, S.M.8
Eberlein, T.J.9
Goedegebuure, P.S.10
Linehan, D.C.11
-
84
-
-
27744477593
-
CD4 + CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer
-
Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T: CD4 + CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005, 14:1269-1273.
-
(2005)
Oncol Rep
, vol.14
, pp. 1269-1273
-
-
Okita, R.1
Saeki, T.2
Takashima, S.3
Yamaguchi, Y.4
Toge, T.5
-
85
-
-
84883681998
-
Natural and induced T regulatory cells in cancer
-
Adeegbe DO, Nishikawa H: Natural and induced T regulatory cells in cancer. Front Immunol 2013, 4:190.
-
(2013)
Front Immunol
, vol.4
, pp. 190
-
-
Adeegbe, D.O.1
Nishikawa, H.2
-
86
-
-
29444442811
-
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
-
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 18538-18543
-
-
Sato, E.1
Olson, S.H.2
Ahn, J.3
Bundy, B.4
Nishikawa, H.5
Qian, F.6
Jungbluth, A.A.7
Frosina, D.8
Gnjatic, S.9
Ambrosone, C.10
Kepner, J.11
Odunsi, T.12
Ritter, G.13
Lele, S.14
Chen, Y.T.15
Ohtani, H.16
Old, L.J.17
Odunsi, K.18
-
87
-
-
49649121241
-
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma
-
Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF: Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008, 14:3156-3167.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3156-3167
-
-
Kline, J.1
Brown, I.E.2
Zha, Y.Y.3
Blank, C.4
Strickler, J.5
Wouters, H.6
Zhang, L.7
Gajewski, T.F.8
-
88
-
-
70350496784
-
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
-
Rech AJ, Vonderheide RH: Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174:99-106.
-
(2009)
Ann N Y Acad Sci
, vol.1174
, pp. 99-106
-
-
Rech, A.J.1
Vonderheide, R.H.2
-
89
-
-
0035903324
-
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
-
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
-
(2001)
J Exp Med
, vol.194
, pp. 823-832
-
-
Sutmuller, R.P.1
van Duivenvoorde, L.M.2
van Elsas, A.3
Schumacher, T.N.4
Wildenberg, M.E.5
Allison, J.P.6
Toes, R.E.7
Offringa, R.8
Melief, C.J.9
-
90
-
-
42649136634
-
Transient T cell depletion causes regression of melanoma metastases
-
Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J: Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6:12.
-
(2008)
J Transl Med
, vol.6
, pp. 12
-
-
Rasku, M.A.1
Clem, A.L.2
Telang, S.3
Taft, B.4
Gettings, K.5
Gragg, H.6
Cramer, D.7
Lear, S.C.8
McMasters, K.M.9
Miller, D.M.10
Chesney, J.11
-
91
-
-
84860713220
-
Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
-
Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikcevich DA, Nelson GD, Yang Z, Grote DM, Ziesmer SC, Silberstein PT, Erlichman C, Witzig TE: Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. Leukemia 2012, 26:1046-1052.
-
(2012)
Leukemia
, vol.26
, pp. 1046-1052
-
-
Ansell, S.M.1
Tang, H.2
Kurtin, P.J.3
Koenig, P.A.4
Nowakowski, G.S.5
Nikcevich, D.A.6
Nelson, G.D.7
Yang, Z.8
Grote, D.M.9
Ziesmer, S.C.10
Silberstein, P.T.11
Erlichman, C.12
Witzig, T.E.13
-
92
-
-
77955175181
-
A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC)
-
Atchison E, Eklund J, Martone B, Wang L, Gidron A, Macvicar G, Rademaker A, Goolsby C, Marszalek L, Kozlowski J, Smith N, Kuzel TM: A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC). J Immunother 2010, 33:716-722.
-
(2010)
J Immunother
, vol.33
, pp. 716-722
-
-
Atchison, E.1
Eklund, J.2
Martone, B.3
Wang, L.4
Gidron, A.5
Macvicar, G.6
Rademaker, A.7
Goolsby, C.8
Marszalek, L.9
Kozlowski, J.10
Smith, N.11
Kuzel, T.M.12
-
93
-
-
27444435581
-
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
-
Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28:582-592.
-
(2005)
J Immunother
, vol.28
, pp. 582-592
-
-
Attia, P.1
Maker, A.V.2
Haworth, L.R.3
Rogers-Freezer, L.4
Rosenberg, S.A.5
-
94
-
-
83255164934
-
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
-
Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer 2011, 11:515.
-
(2011)
BMC Cancer
, vol.11
, pp. 515
-
-
Telang, S.1
Rasku, M.A.2
Clem, A.L.3
Carter, K.4
Klarer, A.C.5
Badger, W.R.6
Milam, R.A.7
Rai, S.N.8
Pan, J.9
Gragg, H.10
Clem, B.F.11
McMasters, K.M.12
Miller, D.M.13
Chesney, J.14
-
95
-
-
84861175955
-
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients
-
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH: CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012, 4:134ra62.
-
(2012)
Sci Transl Med
, vol.4
-
-
Rech, A.J.1
Mick, R.2
Martin, S.3
Recio, A.4
Aqui, N.A.5
Powell, D.J.6
Colligon, T.A.7
Trosko, J.A.8
Leinbach, L.I.9
Pletcher, C.H.10
Tweed, C.K.11
DeMichele, A.12
Fox, K.R.13
Domchek, S.M.14
Riley, J.L.15
Vonderheide, R.H.16
-
96
-
-
84866358651
-
Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment
-
Lu T, Gabrilovich DI: Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res 2012, 18:4877-4882.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4877-4882
-
-
Lu, T.1
Gabrilovich, D.I.2
-
97
-
-
61349100687
-
Myeloid-derived suppressor cells as regulators of the immune system
-
Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
-
(2009)
Nat Rev Immunol
, vol.9
, pp. 162-174
-
-
Gabrilovich, D.I.1
Nagaraj, S.2
-
98
-
-
78049236422
-
Induction of T cell anergy: integration of environmental cues and infectious tolerance
-
Chappert P, Schwartz RH: Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr Opin Immunol 2010, 22:552-559.
-
(2010)
Curr Opin Immunol
, vol.22
, pp. 552-559
-
-
Chappert, P.1
Schwartz, R.H.2
-
99
-
-
0030743846
-
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
-
Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997, 94:8099-8103.
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, pp. 8099-8103
-
-
Kwon, E.D.1
Hurwitz, A.A.2
Foster, B.A.3
Madias, C.4
Feldhaus, A.L.5
Greenberg, N.M.6
Burg, M.B.7
Allison, J.P.8
-
100
-
-
0027946018
-
B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum
-
Chen L, McGowan P, Ashe S, Johnston JV, Hellström I, Hellström KE: B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 1994, 54:5420-5423.
-
(1994)
Cancer Res
, vol.54
, pp. 5420-5423
-
-
Chen, L.1
McGowan, P.2
Ashe, S.3
Johnston, J.V.4
Hellström, I.5
Hellström, K.E.6
-
101
-
-
0030584849
-
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization
-
Gajewski TF, Fallarino F, Uyttenhove C, Boon T: Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 1996, 156:2909-2917.
-
(1996)
J Immunol
, vol.156
, pp. 2909-2917
-
-
Gajewski, T.F.1
Fallarino, F.2
Uyttenhove, C.3
Boon, T.4
-
102
-
-
28544446699
-
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing
-
Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM: Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005, 65:10569-10577.
-
(2005)
Cancer Res
, vol.65
, pp. 10569-10577
-
-
Wang, L.X.1
Li, R.2
Yang, G.3
Lim, M.4
O'Hara, A.5
Chu, Y.6
Fox, B.A.7
Restifo, N.P.8
Urba, W.J.9
Hu, H.M.10
-
103
-
-
12744253307
-
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
-
Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005, 26:111-117.
-
(2005)
Trends Immunol
, vol.26
, pp. 111-117
-
-
Klebanoff, C.A.1
Khong, H.T.2
Antony, P.A.3
Palmer, D.C.4
Restifo, N.P.5
-
104
-
-
33749135271
-
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection
-
Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF: Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 2006, 177:4521-4529.
-
(2006)
J Immunol
, vol.177
, pp. 4521-4529
-
-
Brown, I.E.1
Blank, C.2
Kline, J.3
Kacha, A.K.4
Gajewski, T.F.5
-
105
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
Citrin, D.E.7
Restifo, N.P.8
Robbins, P.F.9
Wunderlich, J.R.10
Morton, K.E.11
Laurencot, C.M.12
Steinberg, S.M.13
White, D.E.14
Dudley, M.E.15
-
106
-
-
84871885298
-
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo
-
Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF: Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 2012, 209:2157-2163.
-
(2012)
J Exp Med
, vol.209
, pp. 2157-2163
-
-
Zheng, Y.1
Zha, Y.2
Driessens, G.3
Locke, F.4
Gajewski, T.F.5
-
107
-
-
37849054022
-
Molecular regulation of T-cell anergy
-
Zheng Y, Zha Y, Gajewski TF: Molecular regulation of T-cell anergy. EMBO Rep 2008, 9:50-55.
-
(2008)
EMBO Rep
, vol.9
, pp. 50-55
-
-
Zheng, Y.1
Zha, Y.2
Gajewski, T.F.3
-
108
-
-
33750093594
-
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha
-
Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF: T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006, 7:1166-1173.
-
(2006)
Nat Immunol
, vol.7
, pp. 1166-1173
-
-
Zha, Y.1
Marks, R.2
Ho, A.W.3
Peterson, A.C.4
Janardhan, S.5
Brown, I.6
Praveen, K.7
Stang, S.8
Stone, J.C.9
Gajewski, T.F.10
-
109
-
-
84877607074
-
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy
-
[Epub ahead of print]
-
Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF: Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol 2013. doi:10.1016/j. molimm.2013.03.006 [Epub ahead of print].
-
(2013)
Mol Immunol
-
-
Zheng, Y.1
Zha, Y.2
Spaapen, R.M.3
Mathew, R.4
Barr, K.5
Bendelac, A.6
Gajewski, T.F.7
-
110
-
-
0025338920
-
LAG-3, a novel lymphocyte activation gene closely related to CD4
-
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T: LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990, 171:1393-1405.
-
(1990)
J Exp Med
, vol.171
, pp. 1393-1405
-
-
Triebel, F.1
Jitsukawa, S.2
Baixeras, E.3
Roman-Roman, S.4
Genevee, C.5
Viegas-Pequignot, E.6
Hercend, T.7
-
111
-
-
78650208859
-
The CD4-like molecule LAG-3, biology and therapeutic applications
-
Sierro S, Romero P, Speiser DE: The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011, 15:91-101.
-
(2011)
Expert Opin Ther Targets
, vol.15
, pp. 91-101
-
-
Sierro, S.1
Romero, P.2
Speiser, D.E.3
-
112
-
-
0344247505
-
cDNA sequences of two inducible T-cell genes
-
Kwon BS, Weissman SM: cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A 1989, 86:1963-1967.
-
(1989)
Proc Natl Acad Sci U S A
, vol.86
, pp. 1963-1967
-
-
Kwon, B.S.1
Weissman, S.M.2
-
113
-
-
84859157752
-
Tim-3, a negative regulator of anti-tumor immunity
-
Anderson AC: Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012, 24:213-216.
-
(2012)
Curr Opin Immunol
, vol.24
, pp. 213-216
-
-
Anderson, A.C.1
-
114
-
-
84877817118
-
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
-
Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M: Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother 2013, 62:629-637.
-
(2013)
Cancer Immunol Immunother
, vol.62
, pp. 629-637
-
-
Baghdadi, M.1
Nagao, H.2
Yoshiyama, H.3
Akiba, H.4
Yagita, H.5
Dosaka-Akita, H.6
Jinushi, M.7
-
115
-
-
36048963838
-
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems
-
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG: LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392.
-
(2007)
J Clin Invest
, vol.117
, pp. 3383-3392
-
-
Grosso, J.F.1
Kelleher, C.C.2
Harris, T.J.3
Maris, C.H.4
Hipkiss, E.L.5
De Marzo, A.6
Anders, R.7
Netto, G.8
Getnet, D.9
Bruno, T.C.10
Goldberg, M.V.11
Pardoll, D.M.12
Drake, C.G.13
-
116
-
-
77952466558
-
Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses
-
Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Jiang B, Chen H: Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses. Cancer Lett 2010, 293:254-262.
-
(2010)
Cancer Lett
, vol.293
, pp. 254-262
-
-
Kuang, Y.1
Weng, X.2
Liu, X.3
Zhu, H.4
Chen, Z.5
Jiang, B.6
Chen, H.7
-
117
-
-
79953087601
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
-
Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J: Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011, 23:286-292.
-
(2011)
Curr Opin Immunol
, vol.23
, pp. 286-292
-
-
Gajewski, T.F.1
Fuertes, M.2
Spaapen, R.3
Zheng, Y.4
Kline, J.5
-
119
-
-
84856069688
-
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma
-
Erratum in: J Clin Oncol 2012, 30:3903
-
Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM: Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30:322-328. Erratum in: J Clin Oncol 2012, 30:3903.
-
(2012)
J Clin Oncol
, vol.30
, pp. 322-328
-
-
Tarhini, A.A.1
Cherian, J.2
Moschos, S.J.3
Tawbi, H.A.4
Shuai, Y.5
Gooding, W.E.6
Sander, C.7
Kirkwood, J.M.8
-
120
-
-
79953295544
-
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity
-
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL: The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
-
(2011)
Cancer Res
, vol.71
, pp. 2488-2496
-
-
Burnette, B.C.1
Liang, H.2
Lee, Y.3
Chlewicki, L.4
Khodarev, N.N.5
Weichselbaum, R.R.6
Fu, Y.X.7
Auh, S.L.8
-
121
-
-
58149177780
-
TLR ligands in the local treatment of established intracerebral murine gliomas
-
Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ: TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008, 181:6720-6729.
-
(2008)
J Immunol
, vol.181
, pp. 6720-6729
-
-
Grauer, O.M.1
Molling, J.W.2
Bennink, E.3
Toonen, L.W.4
Sutmuller, R.P.5
Nierkens, S.6
Adema, G.J.7
-
122
-
-
77949324525
-
Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition
-
Wang Y, Zhu M, Yu P, Fu YX: Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition. J Immunol 2010, 184:1589-1595.
-
(2010)
J Immunol
, vol.184
, pp. 1589-1595
-
-
Wang, Y.1
Zhu, M.2
Yu, P.3
Fu, Y.X.4
-
123
-
-
84862523773
-
LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response
-
Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W: LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res 2012, 72:2980-2989.
-
(2012)
Cancer Res
, vol.72
, pp. 2980-2989
-
-
Zou, W.1
Zheng, H.2
He, T.C.3
Chang, J.4
Fu, Y.X.5
Fan, W.6
-
124
-
-
84861112821
-
Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma
-
Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, Okazaki T, Marumoto T, Takahashi A, Takayama K, Nakanishi Y, Shimizu H, Tani K: Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012, 72:2609-2621.
-
(2012)
Cancer Res
, vol.72
, pp. 2609-2621
-
-
Miyamoto, S.1
Inoue, H.2
Nakamura, T.3
Yamada, M.4
Sakamoto, C.5
Urata, Y.6
Okazaki, T.7
Marumoto, T.8
Takahashi, A.9
Takayama, K.10
Nakanishi, Y.11
Shimizu, H.12
Tani, K.13
-
126
-
-
66149109603
-
Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy
-
Xu L, Xu W, Jiang Z, Zhang F, Chu Y, Xiong S: Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol Ther 2009, 8:66-72.
-
(2009)
Cancer Biol Ther
, vol.8
, pp. 66-72
-
-
Xu, L.1
Xu, W.2
Jiang, Z.3
Zhang, F.4
Chu, Y.5
Xiong, S.6
-
127
-
-
78049276260
-
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma
-
Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T: Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010, 70:7788-7799.
-
(2010)
Cancer Res
, vol.70
, pp. 7788-7799
-
-
Klages, K.1
Mayer, C.T.2
Lahl, K.3
Loddenkemper, C.4
Teng, M.W.5
Ngiow, S.F.6
Smyth, M.J.7
Hamann, A.8
Huehn, J.9
Sparwasser, T.10
-
128
-
-
84879104519
-
Dual blockade of PD-1 and CLTA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
-
Duraiswamy J, Laluza KM, Freeman GJ, Coukos G: Dual blockade of PD-1 and CLTA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013, 73(12):3591-603.
-
(2013)
Cancer Res
, vol.73
, Issue.12
, pp. 3591-3603
-
-
Duraiswamy, J.1
Laluza, K.M.2
Freeman, G.J.3
Coukos, G.4
-
129
-
-
33746924449
-
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
-
Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, Abdessalam SF, Lehman AM, Jarjoura D, Zheng P, Liu Y: Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006, 66:7276-7284.
-
(2006)
Cancer Res
, vol.66
, pp. 7276-7284
-
-
Kocak, E.1
Lute, K.2
Chang, X.3
May, K.F.4
Exten, K.R.5
Zhang, H.6
Abdessalam, S.F.7
Lehman, A.M.8
Jarjoura, D.9
Zheng, P.10
Liu, Y.11
-
130
-
-
84863115998
-
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
-
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
-
(2012)
Cancer Res
, vol.72
, pp. 917-927
-
-
Woo, S.R.1
Turnis, M.E.2
Goldberg, M.V.3
Bankoti, J.4
Selby, M.5
Nirschl, C.J.6
Bettini, M.L.7
Gravano, D.M.8
Vogel, P.9
Liu, C.L.10
Tangsombatvisit, S.11
Grosso, J.F.12
Netto, G.13
Smeltzer, M.P.14
Chaux, A.15
Utz, P.J.16
Workman, C.J.17
Pardoll, D.M.18
Korman, A.J.19
Drake, C.G.20
Vignali, D.A.21
more..
-
131
-
-
77957744369
-
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
-
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
-
(2010)
J Exp Med
, vol.207
, pp. 2187-2194
-
-
Sakuishi, K.1
Apetoh, L.2
Sullivan, J.M.3
Blazar, B.R.4
Kuchroo, V.K.5
Anderson, A.C.6
-
136
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
-
(2013)
N Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
Segal, N.H.7
Ariyan, C.E.8
Gordon, R.A.9
Reed, K.10
Burke, M.M.11
Caldwell, A.12
Kronenberg, S.A.13
Agunwamba, B.U.14
Zhang, X.15
Lowy, I.16
Inzunza, H.D.17
Feely, W.18
Horak, C.E.19
Hong, Q.20
Korman, A.J.21
Wigginton, J.M.22
Gupta, A.23
Sznol, M.24
more..
-
137
-
-
77958012775
-
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy
-
Gajewski TF, Louahed J, Brichard VG: Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
-
(2010)
Cancer J
, vol.16
, pp. 399-403
-
-
Gajewski, T.F.1
Louahed, J.2
Brichard, V.G.3
-
138
-
-
84862769116
-
An immuneactive tumor microenvironment favors clinical response to ipilimumab
-
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V: An immuneactive tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:1019-1031.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 1019-1031
-
-
Ji, R.R.1
Chasalow, S.D.2
Wang, L.3
Hamid, O.4
Schmidt, H.5
Cogswell, J.6
Alaparthy, S.7
Berman, D.8
Jure-Kunkel, M.9
Siemers, N.O.10
Jackson, J.R.11
Shahabi, V.12
-
139
-
-
70350572075
-
Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031)
-
Louahed J, Gruselle O, Gaulis S, Coche T, Eggermont AM, Kruit W, Dreno B, Chiarion Sileni VC, Lehmann F, Brichard VG: Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol 2008, 26. Suppl; abstr 9045).
-
(2008)
J Clin Oncol
, pp. 26
-
-
Louahed, J.1
Gruselle, O.2
Gaulis, S.3
Coche, T.4
Eggermont, A.M.5
Kruit, W.6
Dreno, B.7
Chiarion Sileni, V.C.8
Lehmann, F.9
Brichard, V.G.10
-
140
-
-
79251522796
-
A single center experience with highdose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response
-
Sullivan RJ, Hoshida Y, Brunet J, Tahan S, Aldridge J, Kwabi C, Gardiner E, McDermot D, Golub T, Atkins MA: A single center experience with highdose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol 2009, 27:15S. Abstract 9003.
-
(2009)
J Clin Oncol
, vol.27
, pp. 15S
-
-
Sullivan, R.J.1
Hoshida, Y.2
Brunet, J.3
Tahan, S.4
Aldridge, J.5
Kwabi, C.6
Gardiner, E.7
McDermot, D.8
Golub, T.9
Atkins, M.A.10
-
141
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127ra37.
-
(2012)
Sci Transl Med
, vol.4
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
Chen, S.7
Klein, A.P.8
Pardoll, D.M.9
Topalian, S.L.10
Chen, L.11
|